The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000603314p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
17/09/2025
Date registered
Help: Date registered
14/05/2026
Date last updated
Help: Date last updated
14/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
14/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Assessing the effect of ketamine on disruption of memory reconsolidation in Post Traumatic Stress Disorder
Scientific title
Evaluating the efficacy of ketamine as a memory reconsolidation blocker to reduce trauma-related memories in treatment-resistant individuals with Post-Traumatic Stress Disorder
Additional trial identifiers [1] 315392 0
none
Universal Trial Number (UTN)
Trial acronym
MRT-OK (memory reconsolidation therapy & oral ketamine)
Related trial records

Health condition
Health condition(s) studied:
Mental Health 338896 0
Condition category
Condition code
Mental Health 335191 335191 0 0
Other mental health disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Randomised, double-blind, active placebo-controlled, parallel-group study evaluating the efficacy of oral ketamine as a memory reconsolidation blocker in treatment-resistant PTSD.
Oral ketamine dose will start at 1 mg/kg and titrate up to a maximum of 3 mg/kg as tolerated

-frequency of dosing; once per week;
-overall duration of dosing, six weeks
-Oral dose will be provided as capsules
-whether dosing will be supervised, Yes, it will be supervised by a psychiatrist, a Psychiatry registrar, an anesthetist or a nurse with a doctor available on call.
-whether the dosing will be accompanied by guided therapy or whether dosing will occur without any therapy or guided imagery exercises: Yes the dosing will be accompanied by guided therapy, memory reconsolidation therapy.
-Monitoring of adherence to the intervention : Not applicable
Participants will be asked to reactivate a traumatic memory via a short writing task every week for six weeks, with ketamine dosing to occur following this task. The anticipated time needed to complete the task is about 30 minutes.
Intervention code [1] 332004 0
Treatment: Drugs
Description of the comparator or control
Midazolam will be administered orally at 0.1 mg/kg immediately following memory reactivation. with a maximum single dose of 15mg.
-frequency of dosing; once per week;
-overall duration of dosing, six weeks
-oral dose will be provided as a tablet
-Dosing will be supervised by A psychiatrist or a psychiatry registrar, or a nurse with a doctor available on call,
-Dose will be determined based on participant body weight
-Monitoring of adherence to the Control Treatment : Not applicable
Control group
Placebo

Outcomes
Primary outcome [1] 342806 0
change in CAPS-5 (Clinician-Administered PTSD Scale for DSM-5 ) total score from baseline (Week 0, pre-dose) to Week 18. A reduction of at least 10 points from baseline will be considered a clinically meaningful treatment response.
Timepoint [1] 342806 0
difference between Baseline (visit 1) and visit 18;
Secondary outcome [1] 452193 0
change in CAPS-5 total score from baseline (Week 0, pre-dose) to Week 7. A reduction of at least 10 points from baseline will be considered a clinically meaningful treatment response.
Timepoint [1] 452193 0
Difference between visit 1 (baseline) and visit 7;
Secondary outcome [2] 452196 0
PTSD Checklist for DSM-5 (PCL-5)
Timepoint [2] 452196 0
baseline (Week 1) and follow-up (Week 18),

Eligibility
Key inclusion criteria
1. Men or women, 18-70 years of age.
2. Participants must have a level of understanding sufficient to agree to all tests and examinations required by the protocol and must sign a written informed consent document.
3. Meets criteria for DSM-5 diagnosis of PTSD according to CAPS 5 (CAPS-5 score>33).
4. Treatment resistant PTSD defined as
(a) Minimum 1x trial of an antidepressant (SSRI or SNRI) for minimum of 6 weeks without adequate response OR (b) completed a course of trauma-focused psychotherapy.
5. Antidepressant medications on stable doses (no dosing adjustments/changes for 4
weeks) prior to beginning of the study.
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1. Unwillingness/unable to sign informed consent.
2. Previous or current participation in trauma-exposed therapy and/or ketamine treatment.
3. Evidence of mental retardation, pervasive developmental disorder and/or
moderate/severe cognitive impairment (MMSE score allowed: minimum of 27).
4. Any unstable medical or non-psychiatric CNS condition.
5. Lifetime history of psychosis-related disorder, bipolar disorder I or II disorder, Complex PTSD and dissociative Identity disorder or any condition other than PTSD judged to be the primary presenting psychiatric diagnosis.
6. Moderate to severe traumatic brain injury (mental status change or loss of consciousness greater than30 min; Glasgow Coma Scale 24hours; visible lesion on CT/MRI brain scan).
7. Active alcohol/illicit substance use disorder within 6 months of initial assessment; presence of illicit drugs by positive urine toxicology.
8. For women: pregnancy (confirmed by lab test), initiation of female hormonal treatments within 3 months of screening, or inability/ unwillingness to use a medically accepted contraceptive method during the study.
9. Imminent risk of suicidal/homicidal ideation and/or behaviour with intent and/or plan.


Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
sealed opaque envelopes
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD

Funding & Sponsors
Funding source category [1] 319984 0
Charities/Societies/Foundations
Name [1] 319984 0
Ramsay Hospital Research Foundation
Country [1] 319984 0
Australia
Primary sponsor type
University
Name
University of the Sunshine Coast
Address
Country
Australia
Secondary sponsor category [1] 322514 0
None
Name [1] 322514 0
Address [1] 322514 0
Country [1] 322514 0
Other collaborator category [1] 283664 0
Hospital
Name [1] 283664 0
Ramsay Clinic New Farm
Address [1] 283664 0
Country [1] 283664 0
Australia

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 318522 0
Ramsay Health Care Human Research Ethics Committee A
Ethics committee address [1] 318522 0
Ethics committee country [1] 318522 0
Australia
Date submitted for ethics approval [1] 318522 0
24/04/2026
Approval date [1] 318522 0
Ethics approval number [1] 318522 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 144454 0
A/Prof Wole Akosile
Address 144454 0
Ramsay Clinic New Farm, 22 Sargent Street, New Farm 4005, QLD
Country 144454 0
Australia
Phone 144454 0
+61 0732549100
Fax 144454 0
Email 144454 0
Contact person for public queries
Name 144455 0
Francois Windels
Address 144455 0
Ramsay Clinic New Farm, 22 Sargent Street, New Farm 4005, QLD
Country 144455 0
Australia
Phone 144455 0
+61 0408456130
Fax 144455 0
Email 144455 0
Contact person for scientific queries
Name 144456 0
Wole Akosile
Address 144456 0
Ramsay Clinic New Farm, 22 Sargent Street, New Farm 4005, QLD
Country 144456 0
Australia
Phone 144456 0
+61 0732549100
Fax 144456 0
Email 144456 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.